IMMUNO-ONCOLOGY DRUGS MARKET ANALYSIS

Immuno-oncology Drugs Market, By Treatment Type (Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others), By Disease Type (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On February 2024, Researchers at UF, University of Florida Health Cancer Center have developed a groundbreaking compound that shows promise in enhancing immunotherapy for various cancers. In laboratory and mouse trials focusing on skin and colorectal cancer models, the compound effectively slowed tumor growth by stimulating the body's immune system to target cancer cells, and in some cases, completely eliminated tumors.
In December 2023, GSK plc, multinational pharmaceutical and biotechnology company announced that the European Commission (EC) has granted marketing authorization for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy. This approval is for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer who require systemic therapy.
Gilead Sciences, Inc .and Xilio Therapeutics, Inc. announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, known as XTX301.Xilio Therapeutics, a clinical-stage biotechnology company, specializes in discovering and developing tumor-activated immuno-oncology therapies. Their proprietary tumor-activation platform is utilized to create a pipeline of innovative molecules, including antibodies, cytokines, bispecifics, and cell engagers.